Is Atrium Therapeutics, Inc. (NASDAQ:RNA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Atrium Therapeutics, Inc. at current levels.
Cardiac RNA play trading below book with two genetic cardiomyopathy shots on goal and Alnylam's delivery playbook to copy.
Where RNA is headed
Atrium is the rarest thing in biotech, a sub-$220M market cap company sitting on $200M+ in cash, trading at 0.93x book, with siRNA assets aimed at genetic heart disease where the precedent (Alnylam's Amvuttra in ATTR cardiomyopathy) just rewrote the rules of cardiac economics. By late 2027, the company should be running Phase 1 readouts on ATR-1072 in PRKAG2 syndrome and have IND clearance on ATR-1086 for PLN cardiomyopathy. Those are two ultra-rare genetic diseases with no approved disease-modifying therapy, clear genetic causation, and biomarkers (cardiac MRI, NT-proBNP, troponin) that move fast enough to support accelerated approval pathways.
Read the full Compass Direction on RNA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $13.09).
See the full RNA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Atrium Therapeutics, Inc. (NASDAQ:RNA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Atrium Therapeutics, Inc. at current levels. Cardiac RNA play trading below book with two genetic cardiomyopathy shots on goal and Alnylam's delivery playbook to copy.
What is RNA's Compass Score?
Atrium Therapeutics, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for RNA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the RNA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.